NO934689L - Anvendelse av 4-(4-klorfenyl-sulfonylkarbamoyl)-benzoyl-L-valyl-L-prolin 1(RS)-(1-trifluoracetyl-2-methyl-protyl)amid ved behandling av vas kulaere sykdommer - Google Patents

Anvendelse av 4-(4-klorfenyl-sulfonylkarbamoyl)-benzoyl-L-valyl-L-prolin 1(RS)-(1-trifluoracetyl-2-methyl-protyl)amid ved behandling av vas kulaere sykdommer

Info

Publication number
NO934689L
NO934689L NO934689A NO934689A NO934689L NO 934689 L NO934689 L NO 934689L NO 934689 A NO934689 A NO 934689A NO 934689 A NO934689 A NO 934689A NO 934689 L NO934689 L NO 934689L
Authority
NO
Norway
Prior art keywords
valyl
trifluoroacetyl
chlorophenyl
proline
benzoyl
Prior art date
Application number
NO934689A
Other languages
English (en)
Other versions
NO934689D0 (no
Inventor
Jawehar Lal Mehta
Tom Gustave Per Saldeen
Wilmer Wayne Nichols
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO934689D0 publication Critical patent/NO934689D0/no
Publication of NO934689L publication Critical patent/NO934689L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radar Systems Or Details Thereof (AREA)

Abstract

Anvendelse av elastase-inhibitoren 4-(4-klorfenyl- sulfonylkarbamoyl)benzoyl-L-valyl-L-prolin l(RS)-(1-trifluor- acetyl-2-metylpropyl)amid eller et farmasøytisk godtagbart salt derav, ved behandling av visse vaskulære sykdommer hvor nøytrofiler er invovlert, f.eks. kardiovaskulær sykdom så som myokardial ischemi, cerebrovaskulær sykdom så som slag, peri- fer vaskulær sykdom så som claudicatio intermittens, så vel som ved svekket reperfusjons-tilstander så som slike som er forbundet med rekonstruktiv vaskulær kirurgi.
NO934689A 1991-06-18 1993-12-17 Anvendelse av 4-(4-klorfenyl-sulfonylkarbamoyl)-benzoyl-L-valyl-L-prolin 1(RS)-(1-trifluoracetyl-2-methyl-protyl)amid ved behandling av vas kulaere sykdommer NO934689L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113164A GB9113164D0 (en) 1991-06-18 1991-06-18 Pharmaceutical agent
PCT/GB1992/001087 WO1992022309A1 (en) 1991-06-18 1992-06-17 Use of 4-(4-chlorophenyl-sulphonylcarbamoyl) benzoyl-l-valyl-l-proline 1(rs)-(1-trifluoroacetyl-2-methylpropyl) amide in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
NO934689D0 NO934689D0 (no) 1993-12-17
NO934689L true NO934689L (no) 1993-12-17

Family

ID=10696898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934689A NO934689L (no) 1991-06-18 1993-12-17 Anvendelse av 4-(4-klorfenyl-sulfonylkarbamoyl)-benzoyl-L-valyl-L-prolin 1(RS)-(1-trifluoracetyl-2-methyl-protyl)amid ved behandling av vas kulaere sykdommer

Country Status (12)

Country Link
EP (1) EP0589937B1 (no)
JP (1) JPH06508826A (no)
AT (1) ATE190493T1 (no)
AU (1) AU667307B2 (no)
CA (1) CA2111846A1 (no)
DE (1) DE69230792T2 (no)
DK (1) DK0589937T3 (no)
ES (1) ES2142825T3 (no)
GB (1) GB9113164D0 (no)
GR (1) GR3032825T3 (no)
NO (1) NO934689L (no)
WO (1) WO1992022309A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161051A (ja) * 1996-12-24 2002-06-04 Fujisawa Pharmaceut Co Ltd 脳虚血性疾患等の治療剤
AT406120B (de) 1997-08-28 2000-02-25 Immuno Ag Gewebekleber
US6903244B1 (en) * 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
JP2002541162A (ja) * 1999-04-13 2002-12-03 ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート 発作による脳障害防止法
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
JP7086987B2 (ja) 2017-03-21 2022-06-20 ザ スクリプス リサーチ インスティテュート 銅およびニッケル触媒による脱炭酸ホウ素化反応

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8600263D0 (en) * 1985-01-22 1986-02-12 Ici America Inc Peptide derivatives
ES2129401T3 (es) * 1990-05-24 1999-06-16 Zeneca Ltd Uso de un compuesto terapeutico para el tratamiento de bronquitis.
DK0458536T3 (da) * 1990-05-24 1998-10-19 Zeneca Ltd Terapeutisk middel til behandling og forebyggelse af åndedrætsbesværsyndrom hos voksne
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
GB9014132D0 (en) * 1990-06-25 1990-08-15 Ici Plc Agent for therapy

Also Published As

Publication number Publication date
ATE190493T1 (de) 2000-04-15
DK0589937T3 (da) 2000-07-31
DE69230792D1 (de) 2000-04-20
DE69230792T2 (de) 2000-06-29
AU1900792A (en) 1993-01-12
CA2111846A1 (en) 1992-12-23
GB9113164D0 (en) 1991-08-07
ES2142825T3 (es) 2000-05-01
NO934689D0 (no) 1993-12-17
JPH06508826A (ja) 1994-10-06
AU667307B2 (en) 1996-03-21
EP0589937B1 (en) 2000-03-15
WO1992022309A1 (en) 1992-12-23
EP0589937A1 (en) 1994-04-06
GR3032825T3 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
ITRM980061A0 (it) Procedimento per la produzione di peptidi com proprieta' inibitrici della sintesi ns3 del virus hcv peptidi cosi' ottenibili e peptidi
EP1392293A4 (en) METHOD FOR THE TREATMENT OF TUMORS WITH NORDIHYDROGUAIARETINIC ACID DERIVATIVES
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
ATE504562T1 (de) 7-, 8- und 9-substitutierte tetracyclinverbindungen
FR2708425B1 (fr) Vêtements particulièrement destinés à la pratique des sports.
BR0001375B1 (pt) processo de esterilizaÇço de uma lente de contato.
DK0618190T3 (da) 9-(Substitueret glycyl)amido-6-(substitueret)-5-hydroxy-6-deoxy-tetracycliner
NO20026199D0 (no) Forbindelser for behandling av Alzheimers sykdom
EP0744181A3 (en) Blood chamber
CA2270473A1 (en) Compositions for disinfection of skin and mucous membrane
PT1406898E (pt) Compostos de piperazina substituida e sua utilizacao como inibidores de oxidacao de acidos gordos
IS5027A (is) Lífvirk peptíð, not fyrir þau og vinnsla þeirra
NO934689L (no) Anvendelse av 4-(4-klorfenyl-sulfonylkarbamoyl)-benzoyl-L-valyl-L-prolin 1(RS)-(1-trifluoracetyl-2-methyl-protyl)amid ved behandling av vas kulaere sykdommer
DOP2002000451A (es) Nuevas ciclohexilsulfonas (agentes terapéuticos)
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
CA2189527A1 (en) Novel Elastase Inhibitors
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
IT1274997B (it) Procedimento per la produzione di spazzole nonche' macchina per la produzione di spazzole per l'esecuzione del procedimento
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
IT249448Y1 (it) Pressa-calandra per l'asciugatura di pelli.
DE69927796D1 (de) Verbesserung des Herstellungsverfahrens von Schuhwerk
DE69807392D1 (de) Maschine zum schnellen Trocknen von Geschirr, Essbesteck, Gläsern und ähnlichem
DE60131648D1 (de) Die konzentration von wasserdampf kompensierendes kalibrationsverfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application